State of the Studio

After two months of the release of our latest game Quantum Break, it’s a good time to give you an update on what’s next for us here at Remedy.

First things first: we’ll continue supporting Quantum Break, which became the “biggest-selling new Microsoft Studios published IP this generation”. It’s something we’re extremely proud of, so thank you to all of our fans for making the game a success and our long-time partner Microsoft for helping us create something unique.

Keep playing, giving feedback and spreading the word! We’re working on another update for the game, so stay tuned for details over at our community forums.

As for the future, we have some very exciting news to share. Moving forward, we want to create more games and hopefully get them out more often. In order to achieve this, Remedy has expanded into two game development teams.

For a while now already, we’ve been developing a brand new Remedy game with a new partner. Our second team is working on an early concept, which will turn into another Remedy game sometime in the future.

We can’t wait to show and tell you more about these new projects, but if there’s anything we’ve learned from the past, it’s that we should have the patience to announce games when they’re ready enough. So don’t expect us take the stage at E3 or gamescom this year.

Remedy has developed games for over 20 years. We’re very thrilled about the AAA games we have in the works and where we are as a studio right now. With several positions open, it’s the perfect time to join us!

Finally, we feel that it’s important to set the expectations right and let you, the fans, know that neither of the two projects currently in development is an Alan Wake game. We’re working on something else, but at the same time we’re exploring opportunities in other mediums to tell more Alan Wake stories.

We have plenty of exciting endeavors to come, and we hope you stay along for the ride.

Thomas Puha

Head of Communications

Follow Remedy Entertainment on Twitter, Facebook and Instagram.